3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
5
Stomach Neoplasms
4
Colorectal Neoplasms
4
Liver Neoplasms
3
Colonic Neoplasms
3
Rectal Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Renal Cell
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Microsatellite Unstable Colorectal Cancer
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Gastroesophageal Cancer
1
Endometrial Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Gastric Cancer
1
Interventions
apatinib
9
Paclitaxel
9
Capecitabine
7
Oxaliplatin
6
camrelizumab
5
Cisplatin
5
S 1 (combination)
4
Fluorouracil
3
Docetaxel
3
130-nm albumin-bound paclitaxel
3
titanium silicide
2
Leucovorin
2
Drug Therapy
2
vorolanib
1
trifluridine tipiracil drug combination
1
tipiracil
1
spartalizumab
1
rucaparib
1
relatlimab
1
raltitrexed
1
pazopanib
1
olaparib
1
lobaplatin
1
linrodostat
1
ezogabine
1
endostar protein
1
durvalumab
1
dacomitinib
1
capivasertib
1
Trifluridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Gastric Cancer
×
relatlimab
×
Gastrointestinal
×
Clear all
NCT02935634
2023-06-09
FRACTION-GC
Bristol-Myers Squibb
Phase 2
Completed
190 enrolled
25 charts